Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aura Biosciences (AURA) Other Accumulated Expenses (2020 - 2026)

Aura Biosciences filings provide 7 years of Other Accumulated Expenses readings, the most recent being $7.5 million for Q1 2026.

  • Quarterly Other Accumulated Expenses rose 124.62% to $7.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Mar 2026, up 124.62% year-over-year, with the annual reading at $242000.0 for FY2025, 28.72% up from the prior year.
  • Other Accumulated Expenses hit $7.5 million in Q1 2026 for Aura Biosciences, up from $242000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $7.5 million in Q1 2026 and bottomed at $152000.0 in Q3 2025.
  • Average Other Accumulated Expenses over 5 years is $1.3 million, with a median of $766000.0 recorded in 2023.
  • The largest annual shift saw Other Accumulated Expenses skyrocketed 434.97% in 2024 before it plummeted 85.66% in 2025.
  • Aura Biosciences' Other Accumulated Expenses stood at $325000.0 in 2022, then soared by 187.69% to $935000.0 in 2023, then tumbled by 79.89% to $188000.0 in 2024, then rose by 28.72% to $242000.0 in 2025, then surged by 3014.05% to $7.5 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's Other Accumulated Expenses are $7.5 million (Q1 2026), $242000.0 (Q4 2025), and $152000.0 (Q3 2025).